The Sana device is simple and easy to use at-home. Patients slip the mask over the eyes and insert the earbuds in the ears. It can be used multiple times a day whenever symptoms of pain, anxiety, depression, or fatigue impinge on daily activities, or just at night to fall asleep faster and improve sleep quality. This use-as-needed nature of the device puts the user back in control of their own treatment. Users have frequently reported phrases such as\u00a0\u201cSana has given me back control of my life\u201d\u00a0after participation in our clinical studies.<\/p>\n\n\n\n
The Idea and subsequent decades of research in developing this product to its present scalable, very affordable, and simple to use state, came through the founder Richard Hanbury breaking his back in Yemen and being told he had a maximum of 5 years to live due to the unrelenting and extreme pain that was destroying his body. A short video created by the BBC explain his story and we highly recommend you watch. https:\/\/www.sana.io\/bbc-video<\/a><\/p>\n\n\n\n Although Richard remains in a wheelchair his research which he tested on himself cured him of all the nerve damage pain he was enduring daily, and he is still with us free of pain 32 years later.<\/p>\n\n\n\n With the advancement of technology over the past 20 years and alongside funding through the US Government ; US Department of Defence (DoD), Department of Homeland Security (DHS) and the National Institute of Health (NIH) the Sana device has developed into an easy-to-use and highly effective headset. The headset is a portable, wearable system that delivers self-administered audio-visual neuromodulation sessions in 16-minute sessions for up at least 5 weeks in the acute phase. Each session consists of symmetric, low intensity, coordinated pulses of sound and light (through closed eyelids) delivered at 7.8Hz, 3Hz and 1Hz - inducing through the frequency following response noted in EEG studies. Sana clinical effects appear to come through normalizing the activity of the Default Mode Network (DMN).<\/p>\n\n\n\n This gives Sana multiple applications across pain and mental health, where current drug solutions have harsh long-term side effects and high addiction and dependency risks. <\/p>\n\n\n\n Denovo Neuropathic Pain FDA approval is expected November 2024.<\/p>\n\n\n\n Sana has a Breakthrough Device Designation (BDD) in Fibromyalgia from the US FDA. This is expected to give Sana expedited treatment by CMS (Centres for Medicare and Medicaid in the US) allowing a fast track to reimbursement. <\/p>\n\n\n\n